Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 22, 2014
Pharmacy Choice - News - Pharmaceutical Development - November 22, 2014

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/21/14 - Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer; Patient recruitment in line to secure expected interim analysis in H1 2015
Release date- 20112014- Quebec City, Canada,- Aeterna Zentaris Inc. today announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina in Charleston, South Carolina, for the Company's ongoing multinational, pivotal ZoptEC Phase 3 trial in women with advanced, recurrent or metastatic endometr
11/21/14 - Avaxia Biologics Receives FDA Orphan Drug Designation for AVX-470 for the Treatment of Pediatric Ulcerative Colitis
Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted antibody therapeutics for gastrointestinal diseases, announced today that the US Food and Drug Administration granted Orphan Drug Designation to AVX-470 for the treatment of pediatric ulcerative colitis. AVX-470 is a gut-targeted anti-TNF antibody, which...
11/21/14 - Bacterial Pneumonia & Sepsis Clinical Trials Market Review H2 2014
This report provides elemental information and data relating to the clinical trials on Bacterial Pneumonia& Sepsis.Dallas, TX 11/21/2014 The clinical trial report, Bacterial Pneumonia Global Clinical Trials Review, H2, 2014 "provides data on the Bacterial Pneumonia clinical trial scenario. The report Bacterial Pneumonia Global Clinical
11/21/14 - Basilea reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis
Basel, Switzerland, November 21, 2014- Basilea Pharmaceutica Ltd. reports today that the U.S. Food and Drug Administration announced a public meeting of the Anti-Infective Drugs Advisory Committee to discuss the New Drug Application for the investigational antifungal isavuconazole, which was submitted by a subsidiary of Basilea's licensing partne
11/21/14 - BioSpecifics Technologies Corp. Announces New Data on XIAFLEX for Peyronie's Disease Presented at SMSNA Scientific Meeting
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced new data on XIAFLEX for the treatment of Peyronie's disease from the Phase 2 and the pivotal Phase 3 IMPRESS trials, presented by BioSpecifics' licensee, Auxi
11/21/14 - Canada : Health Canada Clears Immunovaccine to Conduct Phase II Clinical Trial of DPX-Survivac in Recurrent Lymphoma [TendersInfo (India)]
Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced that it has received clearance from Health Canada to conduct a Phase II clinical study of DPX-Survivac in patients with diffuse large B cell lymphoma. The Company-sponsored trial will evaluate DPX-Survivac, Immunovaccine s lead cancer vaccine candidate, in...
11/21/14 - Celgene Receives Positive CHMP Opinion for OTEZLA (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis
BOUDRY, Switzerland Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency s Committee for Medicinal Products for Human Use has adopted a positive opinion for OTEZLA , the Company s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications:
11/21/14 - Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture;...
SUMMARY: The Food and Drug Administration is announcing the availability of a document entitled "Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture; Guidance for Industry" dated December 2014. The guidance announced in this notice finalizes the draft guidance
11/21/14 - CHMP Grants Positive Opinions of AbbVie's VIEKIRAX? (ombitasvir/paritaprevir/ritonavir) + EXVIERA? (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe
The European Committee for Medicinal Products for Human Use of the European Medicines Agency has granted positive opinions for AbbVie's investigational, all-oral, interferon-free treatment of VIEKIRAX?+ EXVIERA? with or without ribavirin for patients with genotype 1 and genotype 4 chronic hepatitis C virus infection. "The CHMP positive opini
11/21/14 - Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva
Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva. Palovarotene, an investigational retinoic acid receptor gamma agonist, is currently in a Phase 2...
11/21/14 - Clinical data of Medigene's Dendritic Cell vaccines to be presented at ASH conference
The Oslo University Hospital has an agreement with Medigene for use of Medigene's new generation DC vaccines for their ongoing academic clinical studies. Furthermore, Medigene informs that an abstract on an investigator initiated phase II clinical trial with Medigene's DC vaccines for the treatment of prostate cancer currently being conducted by th
11/21/14 - Cytori Announces Promising Results in a Feasibility Trial of Cytori Cell Therapy in Conjunction with Anterior Cruciate Ligament Repair
Cytori Therapeutics, Inc. today reported positive results from a clinical study of Cytori Cell Therapy? in anterior cruciate ligament reconstruction of patients with ACL tears. Ramon Cugat, co-director of the Orthopedic Institute, Hospital Quiron Barcelona and the lead investigator of the study, performed autologous bone-patellar tendon-bone...
11/21/14 - EDAP Reports Continued Strong Growth In Third Quarter 2014 [Global Data Point]
Mr. Oczachowski continued, "In the U.S., we recently reached an important milestone in our ongoing regulatory efforts with the receipt of a letter from the FDA. This comprehensive guidance reflects the extensive discussions we have had with the FDA since our Advisory Panel meeting. In addition, we remain steadfastly committed to advancing the FDA a
11/21/14 - EDDA Technology Introduces the Newly FDA-Cleared IQQA-BodyImaging and Cloud-Based OnDemand Services for Imaging-Guided Cancer Treatment
EDDA Technology, a global leading provider in advanced real-time interactive quantitative imaging solutions, announced today that the company has received FDA clearance on IQQA - BodyImaging. The new product will be introduced as the latest addition to the IQQA Platform and Product Suite for imaging-guided cancer treatment at the 100 th Scie
11/21/14 - Enanta Announces CHMP Grants Positive Opinions of AbbVie's VIEKIRAX? (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA? (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that the European Committee for Medicinal Products for Human Use of the European Medicines Agency has granted positive opinions for AbbVie s investigational,.
11/21/14 - European CHMP Adopts Positive Opinion for Genzyme's Cerdelga (eliglustat) Capsules
Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Cerdelga capsules, an oral treatment for certain adults living with Gaucher disease type 1.. The European Commission is expected to make a final decision on gr
11/21/14 - FDAnews Announces Gender Distribution in Device Clinical Trials: The FDA's Increasing Emphasis on Sex-Specific Data Webinar, Dec. 4, 2014
Gender Distribution in Device Clinical Trials: The FDA's Increasing Emphasis on Sex-Specific Data** FDAnews Webinar** Dec. 4, 2014 1:30 p.m. 3:00 p.m. EST http://www.fdanews.com/GenderDistributionDeviceCT. Despite FDA prodding, recent device clinical trials include only 22% women. In August, the FDA issued its long-awaited draft guidance, "Eva
11/21/14 - Findings from Henry Ford Hospital Broaden Understanding of Sleep Research (Electroencephalographic Power Spectral Density Profile of the Orexin...
Findings from Henry Ford Hospital Broaden Understanding of Sleep Research. According to news reporting from Detroit, Michigan, by NewsRx journalists, research stated, "Suvorexant, an orexin receptor antagonist, improves sleep in healthy subjects and patients with insomnia. The news correspondents obtained a quote from the research from Henry Ford H
11/21/14 - GNW-News: Basilea reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis (english)
Basel, Switzerland, November 21, 2014- Basilea Pharmaceutica Ltd. reports today that the U.S. Food and Drug Administration announced a public meeting of the Anti-Infective Drugs Advisory Committee to discuss the New Drug Application for the investigational antifungal isavuconazole, which was submitted by a subsidiary of Basilea's licensing partner.
11/21/14 - Grant brings clinical trials to region [The Free Lance-Star, Fredericksburg, Va.]
Nov. 21 Karen Jackson almost made it to the five-year mark, the momentous milestone when she could be considered cancer-free. But just months before that, she developed a dry cough. Her doctor sent the King George County woman for an X-ray, which showed a mass in her chest.
11/21/14 - Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus
Immunomedics, Inc., today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted orphan status for the use of veltuzumab, the Company's humanized anti-CD20 antibody, for the treatment of pemphigus. "We are pleased to receive the Orphan Drug designation for veltuzumab in pemphigus from the FD
11/21/14 - In Landmark Study of Cell Therapy for Heart Attack, More Cells Make a Difference
Emory University Woodruff Health Sciences Center issued the following news release:. That's a key lesson emerging from a clinical trial that was reported Nov. 17 at the American Heart Association meeting in Chicago. The study was sponsored by NeoStem, Inc. "This was an enormous undertaking, one that broke new ground in terms of assessing cell thera
11/21/14 - Intra-Cellular Therapies Announces Additional Results From Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today presented additional results from ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in health
11/21/14 - InVivo Therapeutics Announces Oregon Health & Science University as Fifth Clinical Trial Site for Neuro-Spinal Scaffold
InVivo Therapeutics Holdings Corp. today announced that the Oregon Health& Science University in Portland, OR is the fifth clinical site in the company s ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury. On October 15, InVivo announced enrollment of its first patient at Barrow Neurological Institute
11/21/14 - J&J -Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate
Release date- 19112014- TITUSVILLE, NJ,- Janssen Research& Development, LLC today announced the submission of a New Drug Application for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. 'This innovative three-month formulation has the potential to positively affect the care of many people with...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
RxSchool
HIV & AIDS Testing & Reporting Guidelines
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415